Optimi Health engages management consultants to


VANCOUVER, British Columbia, November 03, 2021 (GLOBE NEWSWIRE) – Optimi Santé Corp. (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated brand of mushrooms targeting functional compounds as well as new psychedelic compounds focused on the industry. health and wellness, is pleased to announce the engagement of management and communications consultants Kydder Management Group Inc. (“Kydder Group”) to assist with government, regulatory, corporate and policy matters.

Driven by a desire to support change in Canada’s mental health regime, Kydder Group is a regulatory communications firm led by Principal and Founder Michael Kydd, who provides regulatory and policy communications advice to some of the world’s most leading psychedelic therapy, research and biotechnology companies and associations around the world.

The Kydder Group is currently leading Canada’s first Regulatory Approval Protocol (MORA) to change current Health Canada regulations, which will hopefully result in controlled legal access to psilocybin therapy for Canadians in care. palliative and at the end of life. The firm is also leading a national coalition through the Canadian Psychedelic Association focused on physician-assisted dying (MAID) and psychedelic therapy as a worthy quality of life option for Canadians at the end of life.

“Industry has an incredible responsibility to communicate the safety and efficacy of controlled substances through the strictest and strictest scientific and clinical standards,” says Kydd. “Bill Ciprick and the Optimi Health team have a remarkable history of exceeding these standards and they appreciate the importance of building trust and operational excellence with Health Canada and consumers. Their growing presence as a world leader in functional mushroom cultivation and psychoactive formulation research is something I am very happy to be a part of.

Kydder Group was engaged to consult and oversee many key activities, including managing the ongoing relationship with Health Canada, completing the facility inspection process, future distributor license changes, reporting on changes and trends in Health Canada policy, identification of future distribution and export opportunities, and input into future license applications (eg, drug establishment license).

Additional services include intra-industry partnerships and connectivity, as well as the development of the regulatory environment, including participation with other major industry players in the development of regulations for approval, participation in industry calls / meetings with Health Canada on regulatory issues, future appearances before parliamentary committees, meetings with provincial governments to explore socio-economic benefits of therapies and psychedelics, and writing SOPs (at need).

Finally, Kydder Group will handle policy advocacy, including meeting and organizing facility tours with policy makers, staff and other influencers. Overall, consumer and regulatory efforts will be coordinated with Optimi Health’s communications providers to help manage messaging strategy and tactics.

Optimi Health CEO Bill Ciprick said, “We are delighted to welcome Michael and his team as they join us at this critical time in the growth of our business and the industry. Optimi is a group of passionate advocates of innovation in mushroom-based formulations. Since we are pioneers in an industry, we need to make sure our path is aligned to meet the least amount of resistance, which is accomplished through excellence in communication and regulation. Today’s announcement is another positive step towards unlocking the value of the psychedelic market.

On behalf of the Board of Directors,

Bill Ciprick
Chief Executive Officer
Optimi Santé Corp.

Optimi is developing a sophisticated mushroom brand that focuses on the health and wellness markets. With a vertically integrated approach, Optimi intends to grow, extract, process and distribute high quality functional mushroom products at its two facilities totaling 20,000 square feet nearing completion in Princeton, Colombia. -British. To fully investigate the science of mushrooms, the Company obtained a research exemption under the Food and Drug Regulations (FDR) from Health Canada for the scientific use of psilocybin and psilocin by the through its wholly owned subsidiary Optimi Labs Inc. Optimi has also applied for a distributor’s license under the Canada Narcotic Control Regulations governing the possession, distribution, sale, laboratory analysis, and research and development of formulations of psilocybin and psilocin. Optimi is committed to expertly cultivating and producing quality production subject to and in accordance with the conditions of all applicable laws and regulations to ensure safe and superior Canadian mushroom production. For more information: https://optimihealth.ca/.

Investor Relations
Email: investors@optimisanté.ca
Telephone: +1 (778) 930-1321
Web: https://optimihealth.ca/

This press release contains forward-looking statements and forward-looking information within the meaning of Canadian securities laws (collectively, “forward-looking statements”) that relate to Optimi’s current expectations and beliefs about future events. All statements that express or involve discussions regarding expectations, beliefs, plans, goals, assumptions or future events or performance (often, but not always, through the use of words or phrases such as ” will likely result “,” are expected “,” expects “,” will continue “,” is expected “,” anticipates “,” believes “,” estimates “,” intends “,” plans “, “Forecasts”, “projection”, “strategy”, “objective” and “outlook”) are not historical facts and may be forward-looking statements and may involve estimates, assumptions and uncertainties that could cause actual results differ materially from those expressed in these forward-looking statements. No assurance can be given that these expectations will prove to be correct and the forward-looking statements included in this press release should not be improperly relied upon. These statements ations speak only as of the date of this press release. In particular and without limitation, this press release contains forward-looking statements regarding the Company’s potential listing on the Nasdaq, the application for a distributor’s license, the activities proposed to be carried out under the research exemption. of the Company and related activities related to psilocybin and psilocin and the Optimi plans, focus and goals.

Forward-looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond the control of Optimi, which could cause actual results and events to occur. differ materially from those disclosed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the impact and progression of the COVID-19 pandemic and other factors set out in the “Forward-Looking Statements” and “Risk Factors” sections in the final prospectus of the Company dated February 12, 2021. Optimi assumes no obligation to update or revise forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. New factors emerge from time to time, and it is not possible for Optimi to predict all of them or assess the impact of each of these factors or the extent to which one factor, or a combination of factors, may make a difference. so that the results differ materially from those contained in any forward-looking statement. press release are expressly qualified in their entirety by this disclaimer.

The CSE accepts no responsibility for the adequacy or accuracy of this release.

Source link

Leave A Reply

Your email address will not be published.